{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:19:21Z","timestamp":1784193561102,"version":"3.55.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Antibacterial activity of ceftazidime-avibactam (CAZ-AVI) was evaluated against bacterial isolates from children in the United States with a urinary tract infection (UTI) or intra-abdominal infection (IAI) during the 2016\u20132019 International Network for Optimal Resistance Monitoring program. Prevalence of isolates and susceptibility to CAZ-AVI in pediatric and adult patients were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Bacterial isolates were collected from children with a UTI or IAI at 70 US medical centers from 2016 to 2019. The antimicrobial activity of CAZ-AVI and comparator agents was tested by broth microdilution methods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The most prevalent <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic> pathogens in children with UTIs were <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic> (62.5%), <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic> (12.1%) and <jats:italic toggle=\"yes\">Proteus mirabilis<\/jats:italic> (6.2%). Minimum inhibitory concentration 90% values for CAZ-AVI against <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic> (0.25 \u03bcg\/mL) and <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic> (4 \u03bcg\/mL) were identical for children and adults. The most prevalent <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic> pathogens in children with IAIs were <jats:italic toggle=\"yes\">E. coli<\/jats:italic> (57.4%), <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic> (11.1%) and <jats:italic toggle=\"yes\">Enterobacter cloacae<\/jats:italic> species complex (9.3%). All isolates of <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic> from pediatric patients with UTI and IAI were susceptible to CAZ-AVI, including extended-spectrum \u03b2-lactamase phenotypes. Susceptibility of <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic> isolates to CAZ-AVI was 96.2% in children and 98.4% in adults with a UTI: for IAI it was 100% and 97.2%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Contemporary UTI and IAI pathogens collected from US children from 2016 to 2019 exhibited similar prevalence and susceptibilities as isolates collected from adult patients. CAZ-AVI exhibited potent activity against these pathogens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003035","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T07:00:07Z","timestamp":1609743607000},"page":"338-343","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Antimicrobial Activity of Ceftazidime-Avibactam Against Contemporary Pathogens From Urinary Tract Infections and Intra-abdominal Infections Collected From US Children During the 2016\u20132019 INFORM Surveillance Program"],"prefix":"10.1097","volume":"40","author":[{"given":"Lynn-Yao","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Non-Clinical Development & Translational Sciences, AbbVie, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, AbbVie, Madison, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Debabov","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Non-Clinical Development & Translational Sciences, AbbVie, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/JCM.00189-16","article-title":"Diagnosis of urinary tract infections in children.","volume":"54","author":"Doern","year":"2016","journal-title":"J Clin Microbiol"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations.","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"e02252","DOI":"10.1128\/AAC.02252-16","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"39","DOI":"10.25100\/cm.v45i1.1318","article-title":"Resistance profile for pathogens causing urinary tract infection in a pediatric population, and antibiotic treatment response at a university hospital, 2010-2011.","volume":"45","author":"V\u00e9lez Echeverri","year":"2014","journal-title":"Colomb Med (Cali)"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1378\/chest.14-2171","article-title":"Antimicrobial resistance in hospital-acquired Gram-negative bacterial infections.","volume":"147","author":"Mehrad","year":"2015","journal-title":"Chest"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to Gram-negative bacteria.","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.","volume":"277","author":"T\u00e4ngd\u00e9n","year":"2015","journal-title":"J Intern Med"},{"issue":"suppl","key":"R11-20250615","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijantimicag.2011.09.006","article-title":"Antimicrobial therapy of urinary tract infections in children.","volume":"38","author":"Beetz","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"176.e1","DOI":"10.1016\/j.jpurol.2017.12.002","article-title":"Changes in antimicrobial resistance and demographics of UTIs in pediatric patients in a single institution over a 6-year period.","volume":"14","author":"Erol","year":"2018","journal-title":"J Pediatr Urol"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcimb.2015.00045","article-title":"Epidemiology and characteristics of urinary tract infections in children and adolescents.","volume":"5","author":"Hanna-Wakim","year":"2015","journal-title":"Front Cell Infect Microbiol"},{"key":"R14-20250615","first-page":"373","article-title":"Extended-spectrum beta-lactamase bacteria from urine isolates in children.","volume":"20","author":"Degnan","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"e0190910","DOI":"10.1371\/journal.pone.0190910","article-title":"Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a French prospective multicenter study.","volume":"13","author":"Madhi","year":"2018","journal-title":"PLoS One"},{"issue":"suppl_1","key":"R16-20250615","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace.","volume":"215","author":"Logan","year":"2017","journal-title":"J Infect Dis"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the centers for disease control and prevention, 2011-2014.","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J Emerg Surg"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg Infect (Larchmt)"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/00365540903159261","article-title":"Community-acquired complicated intra-abdominal infections in children hospitalized during 1995-2004 at a paediatric surgery department.","volume":"41","author":"Newman","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a Randomized, Controlled, Double-Blind, Phase 3 Program.","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R23-20250615","first-page":"72","article-title":"Epidemiology and antimicrobial susceptibility of Gram-negative pathogens causing intra-abdominal infections in pediatric patients in Europe-SMART 2011-2014.","volume":"6","author":"Lob","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/sur.2017.104","article-title":"Low infection-related re-admission rates in a retrospective of 4725 children with appendicitis using a clinical pathway in a tertiary care pediatric center.","volume":"18","author":"Marino","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/AAC.03074-15","article-title":"Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study.","volume":"60","author":"Miller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jpedsurg.2015.10.024","article-title":"Nonoperative treatment of acute appendicitis in children: a feasibility study.","volume":"51","author":"Hartwich","year":"2016","journal-title":"J Pediatr Surg"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jamcollsurg.2014.02.031","article-title":"Feasibility of a nonoperative management strategy for uncomplicated acute appendicitis in children.","volume":"219","author":"Minneci","year":"2014","journal-title":"J Am Coll Surg"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/INF.0000000000002395","article-title":"Safety and efficacy of ceftazidime-avibactam in the treatment of children \u22653 months to <18 years with complicated urinary tract infection: results from a Phase 2 Randomized, Controlled Trial.","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0000000000002392","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children \u22653 months to <18 years with complicated intra-abdominal infection: results from a Phase 2, Randomized, Controlled Trial.","volume":"38","author":"Bradley","year":"2019","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:03:40Z","timestamp":1750003420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003035","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,21]]}}}